- Home
- KRP vs SNDX Comparison
KRP vs SNDX Comparison
Compare KRP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- SNDX
- Stock Information
- Founded
- KRP 2013
- SNDX 2005
- Country
- KRP United States
- SNDX United States
- Employees
- KRP N/A
- SNDX N/A
- Industry
- KRP Oil & Gas Production
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- SNDX Health Care
- Exchange
- KRP Nasdaq
- SNDX Nasdaq
- Market Cap
- KRP 1.1B
- SNDX 1.3B
- IPO Year
- KRP 2017
- SNDX 2016
- Fundamental
- Price
- KRP $13.53
- SNDX $16.42
- Analyst Decision
- KRP Hold
- SNDX Strong Buy
- Analyst Count
- KRP 5
- SNDX 10
- Target Price
- KRP $17.20
- SNDX $38.40
- AVG Volume (30 Days)
- KRP 455.1K
- SNDX 1.9M
- Earning Date
- KRP 11-06-2025
- SNDX 11-04-2025
- Dividend Yield
- KRP 12.67%
- SNDX N/A
- EPS Growth
- KRP N/A
- SNDX N/A
- EPS
- KRP N/A
- SNDX N/A
- Revenue
- KRP $312,566,668.00
- SNDX $77,933,000.00
- Revenue This Year
- KRP $9.34
- SNDX $642.36
- Revenue Next Year
- KRP $2.80
- SNDX $108.58
- P/E Ratio
- KRP N/A
- SNDX N/A
- Revenue Growth
- KRP N/A
- SNDX 2126.66
- 52 Week Low
- KRP $10.98
- SNDX $8.58
- 52 Week High
- KRP $16.99
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- KRP 46.41
- SNDX 61.98
- Support Level
- KRP $13.38
- SNDX $14.93
- Resistance Level
- KRP $13.83
- SNDX $15.99
- Average True Range (ATR)
- KRP 0.29
- SNDX 0.70
- MACD
- KRP 0.02
- SNDX 0.04
- Stochastic Oscillator
- KRP 30.19
- SNDX 83.26
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.